Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.

We are pleased to share that the video recording for the GOG-3133 FRAmework-01 clinical trial is now available for on‑demand viewing. In this video, Dr. Roisin O'Cearbhaill and Dr. Bhavana Pothuri provide a high-level overview of the study, including the scientific rationale, trial design, and key features of the three cohorts evaluating patients with platinum-resistant and platinum-sensitive ovarian cancer.  We encourage all investigators and research staff involved with GOG-3133 to review the video and share it with members of their study teams. The video is intended to support understanding of the study and prepare sites for successful patient identification and enrollment. Thank you for your continued dedication to advancing ovarian cancer research. If you have any questions about the study, please reach out to the GOG-3133 study team. Contact Study PIs: Roisin O'Cearbhaill, MD Memorial Sloan Kettering Cancer Center ocearbhr@mskcc.org Bhavana Pothuri, MD NYU Langone bhavana.pothuri@nyulangone.org

The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to listen to the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside symposium podcast that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Friday, June 12, 2026. Platinum‑resistant ovarian cancer (PROC) remains a major therapeutic challenge due to modest survival outcomes and frequent treatment resistance. This CME session delivers a science‑forward, methodologic update designed to help clinicians interpret evolving evidence and educate the audience on thoughtful practice-based approach.  Faculty will cover the current treatment landscape and survival benchmarks; mechanisms of resistance that inform next‑generation strategies; a masterclass in interpreting Phase 3 data (design, endpoints, and external validity); and equity and access considerations including biomarker testing logistics, clinical trial access, and shared decision‑making. Through a moderated panel, attendees will contextualize new evidence, anticipate how pending regulatory decisions may impact care, and identify research implications. This educational activity is supported by an independent medical education grant from Corcept Therapeutics

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026. This educational activity is supported by an independent medical education grant from GSK. Course Description The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.